Ngorsuraches S - Search Results

1

Patients' preferences and willingness-to-pay for disease-modifying therapies.

Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches S. Frost N, et al. Among authors: ngorsuraches s. Mult Scler Relat Disord. 2019 Oct;35:55-60. doi: 10.1016/j.msard.2019.07.005. Epub 2019 Jul 9. Mult Scler Relat Disord. 2019. PMID: 31323483

2

Parents' preferences and willingness-to-pay for human papilloma virus vaccines in Thailand.

Ngorsuraches S, Nawanukool K, Petcharamanee K, Poopantrakool U. Ngorsuraches S, et al. J Pharm Policy Pract. 2015 Jul 22;8(1):20. doi: 10.1186/s40545-015-0040-8. eCollection 2015. J Pharm Policy Pract. 2015. PMID: 26199734 Free PMC article.

3

Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.

Ngorsuraches S, Thongkeaw K. Ngorsuraches S, et al. Springerplus. 2015 Nov 5;4:674. doi: 10.1186/s40064-015-1482-9. eCollection 2015. Springerplus. 2015. PMID: 26558177 Free PMC article.

4

Examining the Value of Subsidies of Health Plans and Cost-Sharing for Prescription Drugs in the Health Insurance Marketplace.

Ngorsuraches S, Mort JR. Ngorsuraches S, et al. Am Health Drug Benefits. 2016 Oct;9(7):368-377. Am Health Drug Benefits. 2016. PMID: 27994712 Free PMC article.

5

Value-Based Pricing of Disease-Modifying Therapies for Multiple Sclerosis: Is This Mission Possible?

Ngorsuraches S. Ngorsuraches S. S D Med. 2018 Mar;71(3):134-135. S D Med. 2018. PMID: 29991102 No abstract available.

6

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.

Stenehjem DD, Au TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, Brixner DI. Stenehjem DD, et al. Among authors: ngorsuraches s. Melanoma Res. 2019 Dec;29(6):626-634. doi: 10.1097/CMR.0000000000000572. Melanoma Res. 2019. PMID: 30688762 Free PMC article.

7

Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.

Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Poudel N, et al. Among authors: ngorsuraches s. Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720. Epub 2020 Dec 24. Mult Scler Relat Disord. 2021. PMID: 33429304

8

Estimating the preferences and willingness-to-pay for colorectal cancer screening: an opportunity to incorporate the perspective of population at risk into policy development in Thailand.

Phisalprapa P, Ngorsuraches S, Wanishayakorn T, Kositamongkol C, Supakankunti S, Chaiyakunapruk N. Phisalprapa P, et al. Among authors: ngorsuraches s. J Med Econ. 2021 Jan-Dec;24(1):226-233. doi: 10.1080/13696998.2021.1877145. J Med Econ. 2021. PMID: 33467947 Free article.

9

Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.

Ngorsuraches S, Poudel N. Ngorsuraches S, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):183-195. doi: 10.1080/14737167.2021.1880321. Epub 2021 Feb 2. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33472451 Review.

10

Consumer Preferences and Willingness to Pay for Nutraceuticals: A Discrete Choice Experiment.

Teoh SL, Ngorsuraches S, Lai NM, Chaiyakunapruk N. Teoh SL, et al. Among authors: ngorsuraches s. Value Health Reg Issues. 2021 May;24:167-172. doi: 10.1016/j.vhri.2020.09.003. Epub 2021 Mar 11. Value Health Reg Issues. 2021. PMID: 33714105 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters